What the Medicare GLP-1 Bridge actually costs you (and what it doesn’t)
Starting July 1, 2026, Medicare is introducing a new $50-per-month copay for GLP-1 weight-loss medications — a policy change widely referred to as the “GLP-1 Bridge.” If you are on Medicare and researching semaglutide (Wegovy, Ozempic), tirzepatide (Zepbound), or another GLP-1 drug for weight management, this article explains exactly what the program covers, what it does not, and what you should expect on your next pharmacy bill.
Note: This article covers Medicare policy as of the July 1, 2026 effective date. It is not medical or legal advice. Talk to your doctor about whether a GLP-1 medication is right for you, and contact Medicare or your Part D plan for questions specific to your coverage.
What is the Medicare GLP-1 Bridge?
The Medicare GLP-1 Bridge is a federal cost-sharing mechanism that caps what most Medicare Part D enrollees pay out-of-pocket for covered GLP-1 obesity medications at $50 per month. Before this policy, GLP-1 drugs used for weight loss were not covered by Medicare at all — the Inflation Reduction Act’s 2023 drug negotiation provisions and subsequent rulemaking opened the door for coverage, and the Bridge is the first direct cost-sharing limit applied to this drug class.
In plain terms: if your Part D plan covers your GLP-1 prescription and you meet Medicare’s eligibility criteria, you pay a flat $50 copay at the pharmacy each month rather than a percentage of the drug’s list price (which can exceed $1,000/month for brand-name GLP-1s).
That is a real saving for many people. But there are important limits you need to understand before you count on this number.
What the $50 Bridge does NOT count toward
This is the most important thing to understand, and it is the detail that surprises most people:
The $50 monthly copay does not count toward your Part D deductible, and it does not count toward the $2,100 annual out-of-pocket cap.
Here is what that means in practice:
| Medicare Part D threshold (2026) | Does the $50 GLP-1 Bridge copay count toward it? |
|---|---|
| Annual deductible (up to $590 in 2026) | No |
| $2,100 out-of-pocket cap | No |
| Catastrophic phase spending | No |
Why does this matter?
If you have other Part D-covered medications — blood pressure drugs, cholesterol medication, diabetes supplies — you still pay normal cost-sharing on those drugs as you work through your deductible and toward the $2,100 cap. The $50 GLP-1 copay is a separate, fixed lane. It does not accelerate you through the coverage phases for your other medications.
If your GLP-1 medication is the only prescription drug you take, this distinction matters less. But for the many Medicare beneficiaries who manage multiple chronic conditions, do not assume your total out-of-pocket spending stops at $50/month. You may reach the $2,100 cap through other drug spending, and separately pay $50/month for your GLP-1 on top of that.
If you receive the Low-Income Subsidy (LIS / Extra Help)
Medicare’s Low-Income Subsidy — also called Extra Help — normally reduces or eliminates Part D cost-sharing for qualifying beneficiaries. Full LIS recipients typically pay $0–$3 per prescription.
The GLP-1 Bridge changes this for GLP-1 medications specifically.
Under the Bridge program, LIS recipients will not receive their usual $0–$3 cost-sharing for GLP-1 obesity drugs. Instead, they will pay the same $50/month copay that applies to standard Part D enrollees.
This is a meaningful change for people on fixed incomes who rely on Extra Help to keep medication costs manageable. If you currently receive LIS benefits and are interested in starting a GLP-1 medication after July 1, plan for a $50/month expense that your Extra Help benefit will not offset.
Who qualifies for LIS? Generally, people with limited income and resources — Medicaid dual-eligibles and SSI recipients are automatically enrolled. If you’re not sure whether you qualify, your local State Health Insurance Assistance Program (SHIP) counselor can check at no cost.
When do these changes take effect?
July 1, 2026.
That is approximately five weeks from the date this article was published. If your doctor is discussing starting or continuing a GLP-1 medication, now is a good time to:
- Call your Part D plan and confirm whether your specific medication (Wegovy, Zepbound, etc.) is covered under the Bridge starting July 1.
- Review your plan’s formulary — not all GLP-1 drugs will be on every plan’s covered drug list from day one.
- Ask about the LIS impact if you receive Extra Help, so you can budget for the $50 copay.
- Check for manufacturer savings programs — some drugmakers offer separate patient assistance programs that may stack with or replace what Medicare provides. Your pharmacist or doctor’s office can often help navigate these.
What Traqr users on Medicare should expect
If you track your GLP-1 medications and weight progress in Traqr, here is what changes and what stays the same:
What changes after July 1:
- Your pharmacy cost for a covered GLP-1 under Part D will shift to the flat $50 Bridge copay.
- If you log medication costs in Traqr, update your cost entry to reflect the $50/month figure.
- If you’re on LIS/Extra Help, expect the $50 copay instead of your usual low or zero copay — update your cost tracking accordingly.
What stays the same:
- Traqr’s medication logging, weight tracking, and weekly summary features work the same regardless of your insurance or copay amount.
- You can use Traqr’s notes field to record any pharmacy conversations or plan confirmations so you have a reference when billing questions come up.
If you are newly eligible for a GLP-1 after July 1 because of this coverage change, the getting started section of our blog covers what to expect in the first weeks on medication.
Quick-reference summary
- What: $50/month flat copay for covered GLP-1 obesity drugs under Medicare Part D
- When: Effective July 1, 2026
- Does it count toward your deductible? No
- Does it count toward the $2,100 out-of-pocket cap? No
- LIS / Extra Help recipients: Will pay $50/month — usual $0–$3 cost-sharing does not apply to this drug class under the Bridge
- Action item: Call your Part D plan before July 1 to confirm your specific drug is covered
Have a question about Medicare coverage or GLP-1 costs not answered here? Download Traqr to track your progress, and check back — we’ll update this page as CMS releases additional guidance.